Logo image of BRCN

BURCON NUTRASCIENCE CORP (BRCN) Stock Fundamental Analysis

NASDAQ:BRCN - Nasdaq - CA1208311029 - Common Stock - Currency: USD

0.44  -0.02 (-4.78%)

After market: 0.44 0 (0%)

Fundamental Rating

2

Taking everything into account, BRCN scores 2 out of 10 in our fundamental rating. BRCN was compared to 85 industry peers in the Chemicals industry. Both the profitability and financial health of BRCN have multiple concerns. BRCN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BRCN has reported negative net income.
In the past 5 years BRCN always reported negative net income.
In the past 5 years BRCN always reported negative operating cash flow.
BRCN Yearly Net Income VS EBIT VS OCF VS FCFBRCN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -2M -4M -6M -8M -10M

1.2 Ratios

Industry RankSector Rank
ROA -43.62%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BRCN Yearly ROA, ROE, ROICBRCN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400

1.3 Margins

Industry RankSector Rank
OM -3208.53%
PM (TTM) -4537.09%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BRCN Yearly Profit, Operating, Gross MarginsBRCN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

BRCN does not have a ROIC to compare to the WACC, probably because it is not profitable.
BRCN has more shares outstanding than it did 1 year ago.
The debt/assets ratio for BRCN is higher compared to a year ago.
BRCN Yearly Shares OutstandingBRCN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
BRCN Yearly Total Debt VS Total AssetsBRCN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

2.2 Solvency

BRCN has an Altman-Z score of 37.52. This indicates that BRCN is financially healthy and has little risk of bankruptcy at the moment.
A Debt/Equity ratio of 0.00 indicates that BRCN is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 37.52
ROIC/WACCN/A
WACC8.7%
BRCN Yearly LT Debt VS Equity VS FCFBRCN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10M 20M 30M

2.3 Liquidity

BRCN has a Current Ratio of 3.16. This indicates that BRCN is financially healthy and has no problem in meeting its short term obligations.
BRCN has a Quick Ratio of 3.16. This indicates that BRCN is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 3.16
Quick Ratio 3.16
BRCN Yearly Current Assets VS Current LiabilitesBRCN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

BRCN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -416.56%.
Looking at the last year, BRCN shows a decrease in Revenue. The Revenue has decreased by -8.93% in the last year.
Measured over the past years, BRCN shows a quite strong growth in Revenue. The Revenue has been growing by 13.76% on average per year.
EPS 1Y (TTM)-416.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.29%
Revenue 1Y (TTM)-8.93%
Revenue growth 3Y62.45%
Revenue growth 5Y13.76%
Sales Q2Q%403.84%

3.2 Future

BRCN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.92% yearly.
Based on estimates for the next years, BRCN will show a very strong growth in Revenue. The Revenue will grow by 208.29% on average per year.
EPS Next Y-26.67%
EPS Next 2Y15.47%
EPS Next 3Y8.74%
EPS Next 5Y4.92%
Revenue Next Year489.89%
Revenue Next 2Y285.85%
Revenue Next 3Y230.61%
Revenue Next 5Y208.3%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BRCN Yearly Revenue VS EstimatesBRCN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
BRCN Yearly EPS VS EstimatesBRCN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2020 2021 2022 2023 2024 2025 2026 -0.05 -0.1 -0.15 -0.2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BRCN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BRCN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BRCN Price Earnings VS Forward Price EarningsBRCN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -8.09
BRCN Per share dataBRCN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 0.1 0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.47%
EPS Next 3Y8.74%

More info and screens

0

5. Dividend

5.1 Amount

BRCN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BURCON NUTRASCIENCE CORP

NASDAQ:BRCN (9/9/2022, 8:00:01 PM)

After market: 0.44 0 (0%)

0.44

-0.02 (-4.78%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)08-15 2022-08-15/amc
Earnings (Next)11-14 2022-11-14
Inst Owners6.93%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap47.84M
Analysts85.45
Price Target1.67 (279.55%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 260.47
P/FCF N/A
P/OCF N/A
P/B 2.59
P/tB N/A
EV/EBITDA -8.09
EPS(TTM)-0.07
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.17
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -3208.53%
PM (TTM) -4537.09%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.16
Quick Ratio 3.16
Altman-Z 37.52
F-Score2
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-416.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.29%
EPS Next Y-26.67%
EPS Next 2Y15.47%
EPS Next 3Y8.74%
EPS Next 5Y4.92%
Revenue 1Y (TTM)-8.93%
Revenue growth 3Y62.45%
Revenue growth 5Y13.76%
Sales Q2Q%403.84%
Revenue Next Year489.89%
Revenue Next 2Y285.85%
Revenue Next 3Y230.61%
Revenue Next 5Y208.3%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A